Paper Details

  1. Home
  2. Paper Details

An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).

Author: GeirnaertMarc, NguyenVanessa Quang

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Selpercatinib and pralsetinib are highly selective RET inhibitors approved by the FDA for the treatment of RET-fusion-positive NSCLC. Both drugs showed efficacy for brain metastases. The most common grade 3 or 4 adverse effects of selpercatinib were hypertension, increased ALT level, and increased AST level. The most common grade 3 or 4 adverse effects of pralsetinib were neutropenia, hypertension, and anemia.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: Selpercatinib and pralsetinib are new targeted therapies used to treat patients with non-small cell lung cancer (NSCLC) due to RET gene rearrangements. The objective of this article is to review selpercatinib and pralsetinib in the context of RET-fusion-positive NSCLC. DATA SOURCES: The ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/10781552221147500

データ提供：米国国立医学図書館（NLM）

Selpercatinib and Pralsetinib: Targeted Therapies for RET-Fusion-Positive NSCLC

[RET gene rearrangements] are a type of genetic alteration that can drive the growth of [non-small cell lung cancer (NSCLC)]. This article reviews two new targeted therapies, [selpercatinib] and [pralsetinib], which are specifically designed to inhibit RET. The authors discuss the clinical trials that led to the approval of these drugs and highlight their effectiveness in treating RET-fusion-positive NSCLC, particularly those with [brain metastases].

Selpercatinib and Pralsetinib: Precision Medicine for Lung Cancer

The development of selpercatinib and pralsetinib represents a significant advancement in precision medicine for NSCLC. These targeted therapies offer promising treatment options for patients with RET-fusion-positive NSCLC. The clinical trials have shown encouraging results, particularly for patients with brain metastases.

Understanding the Impact of Targeted Therapies on Lung Cancer Treatment

The emergence of selpercatinib and pralsetinib demonstrates the growing role of targeted therapies in cancer treatment. By focusing on specific genetic alterations, these drugs can effectively target cancer cells while minimizing damage to healthy tissues. This personalized approach is transforming the landscape of cancer treatment.

Dr.Camel's Conclusion

Lung cancer, like a desert mirage, can be deceptive and difficult to conquer. Selpercatinib and pralsetinib, like two skilled desert navigators, offer targeted solutions for those with RET-fusion-positive NSCLC. These drugs, with their precision focus, can help patients navigate the challenging terrain of lung cancer, offering hope for a brighter future.

Date :
  1. Date Completed 2023-02-06
  2. Date Revised 2023-02-06
Further Info :

Pubmed ID

36572992

DOI: Digital Object Identifier

10.1177/10781552221147500

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.